Latamoxef Sodium for Injection: Reading Public Records Before a CMO Inquiry

1. What the cited records show

Five public documents place Hainan Hailing Chemipharma and Latamoxef Sodium for Injection in distinct, dated public contexts. Each is read only within its own stated scope:

• The 2021 Jingan District public medical-institution medicine directory lists a 250 mg/bottle presentation and Hainan Hailing Chemipharma for its defined institutional-directory purpose.
• Fujian’s 2023 public-inquiry listing for newly added supplementary-catalogue medicines lists 0.25 g, 0.5 g and 1.0 g injectable presentations; the document’s manufacturer and applicant fields name Hainan Hailing Chemipharma for those entries.
• Fujian’s Fifth drug volume-procurement selected-products list lists 0.25 g, 0.5 g and 1.0 g lyophilized powder for injection presentations in rows 238–240, with Hainan Hailing Chemipharma in its manufacturer and applicant fields.
• The National Healthcare Security Administration’s GY-YD2024-2 proposed-selection results table records the company, injectable dosage form and 0.25 g × 1 presentation within that national centralized-procurement process.
• Tianjin Healthcare Security Administration’s April 2025 information-maintenance table for the medical-insurance payment scope records Latamoxef Sodium for Injection as a 1.0 g lyophilized powder for injection presentation, with Hainan Hailing Chemipharma named in the manufacturer field. This is a dated local information-maintenance record; it is not a current product-status confirmation.

The issuer, date, product name, presentation and named fields in each record can be checked. The records are not interchangeable with a current dossier or a project decision.

2. What they do not prove

Neither record confirms a current procurement outcome, registration, label, marketing status, supply, price, available capacity, site assignment, release status, target-country status, project acceptance or suitability. A record can remain publicly accessible after its operational context has changed.

3. A disciplined first screen

For a non-confidential CMO/CDMO discussion, state the target market, intended product and presentation, programme stage, required evidence, timing assumption and requested decision. Then test the legal entity, proposed site, current product status, sterile strategy, quality evidence and technology-transfer readiness. Use the lyophilized-product CMO evaluation guide and the non-confidential project-assessment guide to structure that screen.

4. A non-confidential next contact

If the public record is relevant to your enquiry, provide only non-confidential context: target market, public generic name, presentation, stage, cooperation model, timing assumption and the next decision sought. Do not send formulas, detailed processes, unpublished dossiers, patient information or trade secrets before an NDA and controlled disclosure path.

For the wider reading boundary of the supplied catalogue, see Hainan Hailing Product Portfolio: A Responsible First Review. For public-source limits, see the public evidence and verification boundary.